ANTIBODY THERAPEUTICS XCHANGE
EAST COAST 2023
Boston
May 22, 2023

Welcome to hubXchange’s Antibody Therapeutics Xchange East Coast 2023, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing antibody therapeutics, through a series of roundtable discussions.

Discussion topics will cover Target Selection, Lead Identification & Optimization, Formats & Scaffolds, Bi/Multi-Specifics and Emerging Technologies.

Take advantage of this unique highly interactive meeting format designed for maximum engagement and collaboration with your peers.

Please note this is an In-Person meeting.

VENUE DETAILS: Hilton Boston Woburn Hotel, 2 Forbes Road, Woburn MA 01801

SNAPSHOTS OF DISCUSSION TOPICS

  • Considerations and challenges guiding target selection in the development of antibody-based therapeutics for cancer
  • Selecting target pairs for bispecific therapeutic antibody development
  • Strategies and considerations of discovering antibodies against novel targets
  • Challenging targets: Opportunity, vs effort, vs risk: General strategies vs custom approaches: In the end you want the best antibody, no matter what
  • Challenging membrane antibody targets: Brainstorming in-parallel in vivo and in vitro methodologies to identify rare and precious functional Ab candidates
  • Translating MoA of antibodies into in-vivo models
  • Fc engineering for improved antibody druggability
  • Considerations for CAR-T/CAR-NK Cell binder format designs during screening and selections
  • Current Challenges in design of bispecific /chimeric antigen receptors for solid tumors
  • Bi/tri-specific strategies for overcoming cell engager toxicity
  • Developability and solving CMC challenges
  • What is the optimum human CDR-H3 repertoire for antibody discovery?

Full Xchange Agenda

Click on each track for detailed agenda

Target Selection

Time
Titles and Bullets
Facilitator
8:00 – 8:30
Registration 
8:30 – 9:00

Opening Address & Keynote Presentation

9:05 – 10:05

Considerations and challenges guiding target selection in the development of antibody-based therapeutics for cancer

  • What are the key criteria for selecting an antigen target? What specific considerations should be taken into account for tumor-associated antigens?
  • What are the pros and cons of targeting cell surface receptors vs. ligand targets? In the context of cancer, what are the pros and cons of targeting over-expressed self-antigens, cancer germline antigens, and neoantigens?
  • What impact, if any, does tumor type play in guiding target selection (i.e. liquid vs. solid tumors)?
  • What antibody parameters should be considered when selecting an antigen target? Antibody affinity? Epitope? Internalization rate? Other?
  • How does therapeutic modality influence target selection? (i.e. ADC, CAR-T, T-cell engager, conventional mAb)

Senior Director, External Innovation, Janssen

Gadi Bornstein is a member of the External Innovation Team within Discovery, Product Development & Supply (DPDS) at the Johnson & Johnson Innovation Center in Boston. As a senior member of the global External Innovation Team, Gadi has overall strategic and operational responsibility for scouting and evaluation of external opportunities across all biologic drug modalities. Gadi has over twenty years of experience in oncology R&D with an emphasis in preclinical antibody discovery. He has led academic alliances as well as industry partnerships throughout his career. Prior to joining Janssen, Gadi was a Senior Director at TESARO, where he led and directed biologics discovery efforts in immuno-oncology. Before TESARO, Gadi held roles of increasing responsibility at Amgen Fremont Inc. (formerly Abgenix Inc.), AstraZeneca, Pfizer, and Novartis. Gadi received his B.S. in biochemistry from the University of California, Davis and his Ph.D. in biochemistry from the University of Southern California Keck School of Medicine. He completed his postdoctoral training at Stanford University in the Division of Immunology and Rheumatology. He has authored numerous research papers, reviews, as well as book chapters, and is a co-inventor on multiple patents.

Portrait picture of Gadi Bornstein
10:10 – 10:40
1-2-1 Meetings/Networking Break
10:40 – 11:10
1-2-1 Meetings/Networking Break
11:10 – 11:20
Morning refreshments
11:20 – 12:20

Sponsor-led Roundtable

12:20 – 13:20
Networking Lunch
13:20 – 13:50

Spotlight Presentation

13:55 – 14:25
1-2-1 Meetings/Networking Break
14:25 – 14:55
1-2-1 Meetings/Networking Break
15:00 – 15:30
Poster Session
15:35 – 16:35

Selecting target pairs for bispecific therapeutic antibody development

Head of Biologics Research US & Global Head Digital Biologics Platform (ML/AI), Large Molecule Research, Sanofi

15:35 – 15:45
Afternoon refreshments
15:45 – 16:45

Strategies and considerations of discovering antibodies against novel targets

Vice President Immunology, Absci

17:50 – 18:50
Evening Drinks Reception

Partners

Antibody Therapeutics Xchange | East Coast 2023
Register